Does CAPMATINIB Cause Neoplasm progression? 11 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 11 reports of Neoplasm progression have been filed in association with CAPMATINIB (TABRECTA). This represents 0.5% of all adverse event reports for CAPMATINIB.
11
Reports of Neoplasm progression with CAPMATINIB
0.5%
of all CAPMATINIB reports
4
Deaths
2
Hospitalizations
How Dangerous Is Neoplasm progression From CAPMATINIB?
Of the 11 reports, 4 (36.4%) resulted in death, 2 (18.2%) required hospitalization.
Is Neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for CAPMATINIB. However, 11 reports have been filed with the FAERS database.
What Other Side Effects Does CAPMATINIB Cause?
Death (411)
Peripheral swelling (283)
Fatigue (257)
Oedema peripheral (247)
Nausea (240)
Malignant neoplasm progression (178)
Dyspnoea (141)
Oedema (130)
Asthenia (113)
Non-small cell lung cancer (96)
What Other Drugs Cause Neoplasm progression?
PALBOCICLIB (10,885)
SUNITINIB MALATE (1,920)
CYCLOPHOSPHAMIDE (1,588)
CARBOPLATIN (1,370)
AXITINIB (1,315)
DOXORUBICIN (1,276)
LETROZOLE (1,225)
PACLITAXEL (1,180)
CRIZOTINIB (1,161)
VINCRISTINE (1,106)
Which CAPMATINIB Alternatives Have Lower Neoplasm progression Risk?
CAPMATINIB vs CAPREOMYCIN
CAPMATINIB vs CAPSAICIN
CAPMATINIB vs CAPTOPRIL
CAPMATINIB vs CARBAMAZEPINE
CAPMATINIB vs CARBETOCIN